For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

TitleLong-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.
Publication TypeJournal Article
Year of Publication2017
AuthorsOrr AL, Rutaganira FU, de Roulet D, Huang EJ, Hertz NT, Shokat KM, Nakamura K
JournalNeurochem Int
Volume109
Pagination106-116
Date Published2017 Oct
ISSN1872-9754
KeywordsAdministration, Oral, alpha-Synuclein, Animals, Cells, Cultured, Disease Models, Animal, Drug Administration Schedule, Humans, Kinetin, Male, Mice, Mice, Inbred C57BL, Neurodegenerative Diseases, Parkinson Disease, Protein Kinases, Rats, Rats, Long-Evans, Rats, Sprague-Dawley, Rodentia
Abstract

Mutations in the mitochondrial kinase PTEN-induced putative kinase 1 (PINK1) cause Parkinson's disease (PD), likely by disrupting PINK1's kinase activity. Although the mechanism(s) underlying how this loss of activity causes degeneration remains unclear, increasing PINK1 activity may therapeutically benefit some forms of PD. However, we must first learn whether restoring PINK1 function prevents degeneration in patients harboring PINK1 mutations, or whether boosting PINK1 function can offer protection in more common causes of PD. To test these hypotheses in preclinical rodent models of PD, we used kinetin triphosphate, a small-molecule that activates both wild-type and mutant forms of PINK1, which affects mitochondrial function and protects neural cells in culture. We chronically fed kinetin, the precursor of kinetin triphosphate, to PINK1-null rats in which PINK1 was reintroduced into their midbrain, and also to rodent models overexpressing α-synuclein. The highest tolerated dose of oral kinetin increased brain levels of kinetin for up to 6 months, without adversely affecting the survival of nigrostriatal dopamine neurons. However, there was no degeneration of midbrain dopamine neurons lacking PINK1, which precluded an assessment of neuroprotection and raised questions about the robustness of the PINK1 KO rat model of PD. In two rodent models of α-synuclein-induced toxicity, boosting PINK1 activity with oral kinetin provided no protective effects. Our results suggest that oral kinetin is unlikely to protect against α-synuclein toxicity, and thus fail to provide evidence that kinetin will protect in sporadic models of PD. Kinetin may protect in cases of PINK1 deficiency, but this possibility requires a more robust PINK1 KO model that can be validated by proof-of-principle genetic correction in adult animals.

DOI10.1016/j.neuint.2017.04.006
Alternate JournalNeurochem. Int.
PubMed ID28434973
PubMed Central IDPMC5641232
Grant ListC06 RR018928 / RR / NCRR NIH HHS / United States
R01 NS091902 / NS / NINDS NIH HHS / United States
T32 GM064337 / GM / NIGMS NIH HHS / United States